A practical reference on albumin conjugate: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-24. Anything still debated is marked as such rather than presented as settled.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
== Structure == CGB is composed of 165 amino acids, and has a molecular weight of 17.739 kDa. On this polypeptide, there are 7 total sites of glycosylation, encompassing 28 total N-linked glycans at 2 sites and 15 total O-linked glycans at 5 sites. The sites of N-glycoslylation occur at Asn33 and Asn50. The sites of O-glycoslyation occur at Ser138, Ser141, Ser147, Ser152, and Ser158. There are also three sites of phosphorylation, occurring at Ser86, Ser116, and Thr117. There are six disulfide pairings, occurring at 9-57, 23-72, 26-110, 34-88, 38-90, and 93-100. Additionally, there are 10 known locations of mutation on the CGB polypeptide, occurring at amino acid positions 33, 35, 50, 52, 137, 138, 141, 147, 152, and 158. There is an alpha helix from amino acid positions 1-15, and a turn from positions 115-117. There are also beta sheets from positions 47-60, 67-69, 75-88, 99-112, and 118-121. The polypeptide of CGB is also unusually flexible when compared to other polypeptides of similar structure and function. Its level of glycosylation has also been referred to as an 'extreme concentration', with baseline Human Chorionic Gonadotropin (hCG) being 30% glycosylated by weight, up to the 42% glycosylation of the 'hyperglocysolated hCG' by weight. The whole hCG protein hormone is a heterodimer, with an alpha and a beta subunit. The alpha subunit is identical in the hCG protein hormone, the Luteinizing Hormone (LH), the Follicle Stimulating Hormone (FSH), and the Thyroid Stimulating Hormone (TSH).
6 April – The new England women's national football team home kit is worn for its inaugural match as England participates in the 2023 Women's Finalissima against Brazil. At Wembley Stadium, England beat Brazil 4–2 in a penalty shootout to win their first Finalissima. 8 April – The NASUWT is to ballot its members on strike action after 87% of those who voted rejected the government's pay offer for teachers in England, which the union says fails to address concerns over pay and conditions. 11 April – Junior doctors in England begin a four-day strike. 14 April – Two police officers are dismissed from the Metropolitan Police over offensive WhatsApp messages, some of them including offensive comments about model Katie Price's son, Harvey. The Royal College of Nursing rejects a pay offer for nurses in England and announces a 48-hour strike from 8pm on 30 April to 8pm on 2 May. UNISON confirms its members working for the NHS have voted unanimously to accept a 5% pay offer from the UK government. Following a trial at Derby Crown Court, Stephen Boden and partner Shannon Marsden are convicted of the murder of their ten-month-old son Finley Boden on Christmas Day 2020, 39 days after he had been returned to them by social services. 15 April – Merseyside Police say that 118 people have been arrested at Aintree Racecourse after protestors delay the start of the 2023 Grand National. The race, which is delayed by 14 minutes, is won by Corach Rambler, ridden by Derek Fox.
The major benefit of the indirect methodology is that conventional achiral stationary phase/mobile phase system may be used for the separation of the generated diastereomers. Thus, considerable flexibility in chromatographic conditions is available to achieve the desired separation and to eliminate interferences from metabolites and endogenous substances. Moreover, the sensitivity of the method can be enhanced by sensible choice of the CDA and the chromatographic detection system. But this indirect approach to enantiomeric analysis has some potential problems. These include availability of a suitable functional group on the enantiomer for derivatization, enantiomeric purity of the CDA, racemization of the CDA during derivatization, and racemization of the analyte during the derivatization. Currently, however, the application of indirect analytical approaches is in decline.
In June 1964, 144 test persons survived for six days in a civilian nuclear bunker. The bunker in Dortmund had been built during the Second World War and had been converted at great expense in the early 1960s into a nuclear-weapon-proof building. However, it would be impossible to build a bunker for millions of German citizens. The Swiss Army built about 7800 nuclear fallout shelters in 1964. In the United States in particular, but also Europe, citizens built private fallout shelters in their front yards on their initiative. This construction was largely kept secret because the owners feared that third parties might take possession of the bunker in the event of a crisis.
Sources: en.wikipedia.org
Extrapyramidal side effects such as: (which usually become apparent soon after therapy is begun or soon after an increase in dose is made) Muscle rigidity Hypokinesia Hyperkinesia Parkinsonism Tremor Akathisia Dystonia Dry mouth Constipation Hypersalivation – excessive salivation Blurred vision Diaphoresis – excessive sweating Nausea Dizziness Somnolence Restlessness Insomnia Overactivity Headache Nervousness Fatigue Myalgia Hyperprolactinemia and its complications such as: (acutely) Sexual dysfunction Amenorrhea – cessation of menstrual cycles Gynecomastia – enlargement of breast tissue in males Galactorrhea – the expulsion of breast milk that's not related to breastfeeding or pregnancy and if the hyperprolactinemia persists chronically, the following adverse effects may be seen: Reduced bone mineral density leading to osteoporosis (brittle bones) Infertility Dyspepsia – indigestion Abdominal pain Flatulence Nasal congestion Polyuria – passing more urine than usual Uncommon (0.1–1% incidence) adverse effects include
However, several subsequent meta-analyses with more trials and patients found no increase in mortality with selegiline added to levodopa. If selegiline does increase mortality, it has been theorized that this may be due to cardiovascular side effects, such as its amphetamine-related sympathomimetic effects and its MAO inhibition-related hypotension. Although selegiline does not seem to increase mortality, it appears to worsen cognition in people with Parkinson's disease over time. Conversely, rasagiline does not seem to do so and can enhance cognition. Rarely, selegiline has been reported to induce or exacerbate impulse control disorders, pathological gambling, hypersexuality, and paraphilias in people with Parkinson's disease. However, MAO-B inhibitors like selegiline causing impulse control disorders is uncommon, controversial, and less frequent than with dopamine receptor agonists like pramipexole. Impulse control disorders with dopaminergic agents have been linked specifically to activation of dopamine D3 receptors in the globus pallidus. Selegiline has also been reported to activate or worsen rapid eye movement (REM) sleep behavior disorder (RBD) in some people with Parkinson's disease. Selegiline has shown little or no misuse potential in humans or monkeys. Likewise, it has no dependence potential in rodents. This is in spite of its amphetamine active metabolites, levomethamphetamine and levoamphetamine, and is in contrast to agents like dextroamphetamine and dextromethamphetamine.
Hemoglobin D – (α2βD2) – A variant form of hemoglobin. Hemoglobin H (β4) – A variant form of hemoglobin, formed by a tetramer of β chains, which may be present in variants of α thalassemia. Hemoglobin Barts (γ4) – A variant form of hemoglobin, formed by a tetramer of γ chains, which may be present in variants of α thalassemia. Hemoglobin S (α2βS2) – A variant form of hemoglobin found in people with sickle cell disease. There is a variation in the β-chain gene, causing a change in the properties of hemoglobin, which results in sickling of red blood cells. Hemoglobin C (α2βC2) – Another variant due to a variation in the β-chain gene. This variant causes a mild chronic hemolytic anemia. Hemoglobin E (α2βE2) – Another variant due to a variation in the β-chain gene. This variant causes a mild chronic hemolytic anemia. Hemoglobin AS – A heterozygous form causing sickle cell trait with one adult gene and one sickle cell disease gene Hemoglobin SC disease – A compound heterozygous form with one sickle gene and another encoding hemoglobin C. Hemoglobin Hopkins-2 – A variant form of hemoglobin that is sometimes viewed in combination with hemoglobin S to produce sickle cell disease.
Commonly, a faggot consists of minced pork liver and heart, with onion and breadcrumbs. The mixture is shaped by hand into small balls, wrapped with caul fat (the omentum membrane from the pig's kidney) and baked. Faggots may also be made with beef. Another variation of the faggot is pig's fry (testicles) wrapped in pig's caul: the pig's fry and boiled onions are minced (ground) together, then mixed with breadcrumbs or cold boiled potatoes, seasoned with sage, mixed herbs and pepper, all beaten together and then wrapped in small pieces of caul to form a ball. They are baked in the oven, and usually served cold.
The most important contribution to the science of controlled release include: (1) the development of polymers and copolymers of N-(2-hydroxypropyl)methacrylamide (HPMA) as drug carriers; (2) the introduction of enzymatically degradable derivatives of these polymers; (3) fundamental studies of the rates of enzymatic degradation of oligopeptide side-chains in polymers; (4) determination of the relationship between polymer structure and rates of pinocytic uptake of those polymers into cells; (5) design and preparation of polymers capable of specific intralysosomal release of chemically bound therapeutic agents; (6) fundamental studies of tissue localization of polymeric carriers bearing ligands for receptors expressed on the surfaces of specific target cells. Three HPMA copolymer - anticancer drug conjugates were in Phase I/II clinical trials.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.